Table 2 Confirmation methods and treatment of CNS aspergillosis in patients with leukemia or stem cell transplantations
Confirmation methods | Â |
 Histopathological examination (HE) | 39% |
 HE and culture | 18.70% |
 Culture | 5% |
 Post-mortem | 5% |
 Aspergillus galactomannan (GM) | 8.50% |
 GM assay and PCR | 1.70% |
 PCR | 1.70% |
 Non-CNS samples | 20.40% |
Medical imaging modalities |  |
 Ring enhancing lesions | 57% |
 Perifocal edema on MRI | 56% |
 Brain hemorrhages | 3.30% |
 Nonspecific hyper intense foci | 1.70% |
Treatment | Â |
 Amphotericin B | 76% |
 Voriconazole | 64% |
 Caspofungin | 18.60% |
 Itraconazole | 15.20% |
 Isavuconazole | 8.50% |
 Flucytosine | 6.70% |
 Micafungin | 6.70% |
 Fluconazole | 5% |
 Posaconazole | 5% |
 Surgery | 39% |